Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1736
- Registration Number
- NCT04437511
- Locations
- 🇺🇸
Kaizen Brain Center, La Jolla, California, United States
🇺🇸Ezy Medical Research, Miami, Florida, United States
🇺🇸Columbus Memory Center, LLC, Columbus, Georgia, United States
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
- Conditions
- COVID-19
- Interventions
- Drug: LY3819253Drug: LY3853113Drug: PlaceboDrug: LY3832479
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3307
- Registration Number
- NCT04427501
- Locations
- 🇺🇸
B S & W Med Center, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Bio-Medical Research, LLC, Miami, Florida, United States
A Study of LY3502970 in Participants With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY3502970Drug: Placebo
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT04426474
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
A Study of Baricitinib (LY3009104) in Participants With COVID-19
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1525
- Registration Number
- NCT04421027
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Westchester General Hospital, Miami, Florida, United States
🇺🇸Community Hospital South, Indianapolis, Indiana, United States
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: LY3819253Drug: Placebo
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT04411628
- Locations
- 🇺🇸
Temple Univ School of Med, Philadelphia, Pennsylvania, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
- Conditions
- Diabetes Mellitus, Type 2OverweightObesity
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT04407234
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 44
- Registration Number
- NCT04408924
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇫🇷Hopital Europeen Georges Pompidou, Paris, France
🇺🇸University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1633
- Registration Number
- NCT04396236
- Locations
- 🇯🇵
Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵Nagaseki Headache Clinic, Kai, Yamanashi, Japan
🇯🇵Hiroshima City Hospital, Hiroshima, Japan
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1000
- Registration Number
- NCT04396574
- Locations
- 🇺🇸
Medical Research Partners - Logan, Logan, Utah, United States
🇺🇸Central Research Associates, Birmingham, Alabama, United States
🇺🇸Rehabilitation & Neurological Services, Huntsville, Alabama, United States
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1188
- Registration Number
- NCT04392154
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Modern Research Associates, Dallas, Texas, United States
🇺🇸Paddington Testing Company Inc, Philadelphia, Pennsylvania, United States